Review
Open access
Oct 2026
Empagliflozin’s role in cardiometabolic disease treatment: an Egyptian expert’s view
EMPA extends beyond glucose-lowering by reducing cardiorenal morbidity and mortality in patients with or without diabetes, supporting its suitability for the large Muslim population.
S. H. Assaad-Khalil, Fawzy Elmessallamy, K. E. Elhadidy et al.
· Diabetology & Metabolic Synd... · 0 citations